Sign In
Buy ATHE
$4.93
+0.0500 (+1.02%)
At Close: Jun 22, 2026
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder
11:41am, Tuesday, 09'th Jun 2026
Alterity Therapeutics Limited (NASDAQ:ATHE) stock is up during Tuesday's session as the biotechnology company announced an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regar
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
07:05am, Tuesday, 09'th Jun 2026
– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration –
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
07:25am, Tuesday, 19'th May 2026
– Alterity's novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA –
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in pat
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
07:25am, Thursday, 07'th May 2026
MELBOURNE, Australia and SAN FRANCISCO, May 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to deve
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
07:25am, Thursday, 30'th Apr 2026
Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSA Advancing ATH434 toward pivotal Phase 3 program; on track for E
Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy Transcript
MELBOURNE, Australia and SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to de
- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale - - Effects seen on both daily function and neurological examination, consistent with previo
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
07:25am, Friday, 17'th Apr 2026
MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to de
Head to Head Contrast: NovoCure (NASDAQ:NVCR) versus Alterity Therapeutics (NASDAQ:ATHE)
01:11am, Thursday, 16'th Apr 2026
NovoCure (NASDAQ: NVCR - Get Free Report) and Alterity Therapeutics (NASDAQ: ATHE - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Up 139.4% in March
01:30am, Tuesday, 14'th Apr 2026
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) was the recipient of a large increase in short interest during the month of March. As of March 31st, there was short inte
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
07:25am, Monday, 30'th Mar 2026
Alignment reached on key elements of ATH434 Phase 3 development program Alignment reached on key elements of ATH434 Phase 3 development program
Alterity Therapeutics Conference: ATH434 Phase II MSA Data, FDA Talks Next, Phase III Set
03:07am, Thursday, 26'th Mar 2026
Alterity Therapeutics (NASDAQ: ATHE) outlined its development strategy for lead drug candidate ATH434, highlighting positive Phase II data in multiple system atrophy (MSA), planned regulatory interact
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Short Interest Up 69.4% in February
03:50am, Sunday, 15'th Mar 2026
Alterity Therapeutics Limited - Sponsored ADR (NASDAQ: ATHE - Get Free Report) saw a large growth in short interest during the month of February. As of February 27th, there was short interest totaling
